CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer
Benzodiazepinones
Immunoconjugates
Lung Neoplasms
Carbazoles
Apoptosis
Mice, SCID
Brief Communication
Antibodies, Monoclonal, Humanized
Prognosis
Small Cell Lung Carcinoma
Xenograft Model Antitumor Assays
3. Good health
Mice
03 medical and health sciences
0302 clinical medicine
Drug Resistance, Neoplasm
Mice, Inbred NOD
Antineoplastic Combined Chemotherapy Protocols
Tumor Cells, Cultured
Animals
Humans
Cell Proliferation
DOI:
10.1038/s41416-020-01192-x
Publication Date:
2020-12-01T02:03:26Z
AUTHORS (6)
ABSTRACT
Abstract Small cell lung cancer (SCLC) is characterised by high relapse rates. Tumour-initiating cells (TICs) are responsible for drug resistance and recurrence of cancer. Rovalpituzumab tesirine (Rova-T), a potent humanised antibody–drug conjugate, selectively targets delta-like protein 3, which highly expressed in SCLC TICs. The experimental CBL0137 (CBL) inhibits the histone chaperone FACT (facilitates chromatin transcription), required expression transcription factors that essential TIC maintenance. Rova-T CBL each target TICs as single agents. However, acquired or intrinsic to agents major problem Therefore, we investigated potential effect combining eradicate more effectively. Our preclinical studies report novel translatable therapeutic strategy dual targeting using combination with potentially increase survival patients.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (13)
CITATIONS (8)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....